Arvinas

Update in progress

ARVN (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Arvinas is a clinical‑stage biotechnology company developing PROTAC-based protein degraders to remove disease‑causing proteins. Its programs include ARV-102 for neurodegenerative diseases (LRRK2, e.g., Parkinson’s), ARV-806 (KRAS G12D), ARV-393 (BCL6) for relapsed NHL, ARV-027 (polyglutamine-expanded AR in muscle), and vepdegestrant (ER) for ER+/HER2− breast cancer. It also develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766) for metastatic CRPC. Partnerships: Pfizer, Genentech, Roche, Carrick, Bayer. Founded 2013, New Haven, CT.

Company score

Sentiment: 0.05; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.05; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.00; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.02; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.02; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive